6-arylalkylamino2,3,4,5-tetrahydro-1H-benzo(d)azepine s as 5-HT2c receptor agonists
Details for Australian Patent Application No. 2006287202 (hide)
International Classifications
Event Publications
21 February 2008 PCT application entered the National Phase
PCT publication WO2007/028083 Priority application(s): WO2007/028083
13 March 2008 Corrigenda
PCT applications that have entered the National Phase - Name Index Under the name Eli Lilly and Company, Application No. 2006287202, Under INID (54), correct the title to 6-arylalkylamino2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2006287207-Methods for enhancing the dewaterability of sludge with alpha-amylase treatment
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser